• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BBY
Click for more information
0.00% 0.0¢

BRADFORD & BINGLEY PLC

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
BBY
BBY 13cent valuation buy rating 		24/06/14 0 2.3K
24/06/14 Last post  Microcapper Comments Created with Sketch.  0  Views Created with Sketch.  2.3K 
BBY
Ann: Removal from Official List at close 31/12/20 		31/12/08 0 2.2K
31/12/08 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  2.2K 
BBY
and bbi...up and down autobots 		03/12/08 1 2.7K
03/12/08 Last post  one-up Comments Created with Sketch.  1  Views Created with Sketch.  2.7K 

See All Discussions arrow Created with Sketch.

Featured News

NEWS Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03
right-arrow Created with Sketch.
NEWS High-grade gold discovery at Didievi Project: First drill results reveal impressive 33m intercept at 2.4g/t
right-arrow Created with Sketch.
NEWS Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial
right-arrow Created with Sketch.
NEWS Positive diamond results allow for scoping study update
right-arrow Created with Sketch.
NEWS Significant shallow gold intersections at Tambourah King reveal potential extensions to the lode gold system, with promising RC drill results and more assays pending
right-arrow Created with Sketch.
NEWS Significant increase in revenue from faster NDIS approvals and launch of new leasing programs
right-arrow Created with Sketch.

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program Arika Resources Ltd has received commitments from investors in support of a Placement worth $3.2 million to support gold exploration in WA
Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03 Nyrada Inc has completed an in-vivo micronucleus on the effects of its NYR-BI03 drug on rats, suggesting it causes no genetic damage
Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.

Featured News

NEWS Antler Copper Project hits major permitting milestone – air quality permit advances to final review
right-arrow Created with Sketch.
NEWS Significant increase in revenue from faster NDIS approvals and launch of new leasing programs
right-arrow Created with Sketch.
NEWS Positive diamond results allow for scoping study update
right-arrow Created with Sketch.
NEWS See what company has secured $98M, 8-year contract renewal with Mercy Health
right-arrow Created with Sketch.
LU7 Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
right-arrow Created with Sketch.
NEWS High-grade gold discovery at Didievi Project: First drill results reveal impressive 33m intercept at 2.4g/t
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.